Plain English summary
U sual treatment when a child arrives at a hospital emergency department with a severe infection and shock is to give liberal amounts of fluid via an injection into a vein (fluid bolus therapy). However, this is based on weak evidence. A group of doctors and researchers came together and proposed the Fluids in Shock (FiSh) trial, which aimed to find out whether or not giving less fluid is beneficial.
Before a large trial is carried out, it is important to answer the question, 'can this trial be done?'. The FiSh feasibility study aimed to do this. First, we conducted an interview study asking parents for their views on the proposed trial and the acceptability of research without prior consent (RWPC), that is, delaying the research discussion and consent seeking until after their child has been given emergency trial treatmentsan approach that has been used successfully in previous studies. Second, we conducted a pilot trial (a small version of the FiSh trial) to test important factors, such as number of children recruited and if doctors and nurses followed the trial protocol properly. Hospital staff and parents of children who participated in the pilot were interviewed for feedback.
In the initial interview study, the 21 parents interviewed supported both the FiSh trial and the use of RWPC. In the pilot trial, 75 children were recruited from 13 hospitals in England. Children were randomly allocated to receive either liberal (currently recommended volume) or smaller fluid boluses. Recruitment was close to the expected level (one patient per hospital per month) and hospitals usually gave the correct volume of fluid in each group. However, participants were a lot less sick than expected, with only a minority needing intensive care and most requiring only one fluid bolus to show improvement. Overall, parents and hospital staff supported the study.
HTA programme
The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.
The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.
For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta
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